Life sciences companies have been one of the most regulated industries over the past 10 to 15 years, with a significant number of Foreign Corrupt Practices Act (FCPA) enforcements in total. There are prevalent signals in both messaging and actions from regulators that indicate a potential significant increase in enforcement. The U.S. deputy attorney general indicated that corruption and white-collar crime is a priority of the Biden administration, noting a ramp-up of additional resources to the criminal division’s fraud section, which is tasked with investigating FCPA cases.
In the Risk and Compliance magazine mini-roundtable interview, KPMG Forensic panelists answer some of the top questions on FCPA and anti-corruption strategies for the life sciences industry. The mini-roundtable covers:
FCPA and Anti-Corruption Strategies for the Life Sciences IndustryDownload PDF
Following the data where others couldn’tRead more